Introduction and objectives
Androgen deprivation therapy (ADT) is commonly used to treat men with locally advanced or advanced prostate cancer. Men on ADT commonly experience a number of side effects and often report unmet supportive care needs. An essential part of any quality cancer support is survivorship care. Unfortunately, survivorship care is often not optimally delivered, or easily accessible, and there is currently no survivorship care model for men on ADT. We are undertaking a randomised trial of tele-based nurse-led survivorship care with prostate cancer survivors undergoing ADT to:
Methods
This is an effectiveness-implementation hybrid (Type 1) trial with participants randomised to one of two arms: i) minimally enhanced usual care; and ii) nurse-led Prostate Cancer Survivorship Essentials (PCEssentials) delivered over four tele-based sessions, with a booster session five months after session one. Eligible participants are Australian residents with prostate cancer commencing ADT and expected to be on ADT for a minimum of 12 months. Participants are followed-up at 3-, 6-, and 12-months post-recruitment. Primary outcomes are HRQoL and self-efficacy. Secondary outcomes are psychological distress, insomnia, fatigue, and physical activity. A concurrent process evaluation with participants and study stakeholders will be undertaken to determine effectiveness of delivery of PCEssentials.
Conclusions
ADT is associated with multiple, often debilitating side effects. There is an urgent need for survivorship care in this patient cohort. This study will provide effectiveness and implementation data to inform the potential for implementation of PCEssentials at scale to address this gap.